McMichael Katherine S, Adams Katie, Breden Crouse Ericka L
St. Joseph's Hospital, Tampa, Florida.
Consult Pharm. 2013 Sep;28(9):584-91. doi: 10.4140/TCP.n.2013.584.
This case describes a 76-year-old African-American female with a history of depression, breast cancer, and hypothyroidism admitted to the inpatient geriatric psychiatry unit for an electroconvulsive therapy (ECT) evaluation. She had one previous episode of depression, which began after a lumpectomy in 2007. Her home medication regimen included tamoxifen 20 mg daily. This case highlights the incidence of depression in persons with breast cancer, examines the controversy of tamoxifen-induced depression, and evaluates antidepressant considerations regarding potentially efficacy-reducing cytochrome P450 2D6 drug interactions with tamoxifen. The pharmacy team played an active role in educating the medical team regarding tamoxifen drug interactions. After many discussions, the patient was ultimately treated with mirtazapine 15 mg at bedtime, in addition to ECT.
该病例描述了一名76岁的非裔美国女性,有抑郁症、乳腺癌和甲状腺功能减退病史,因接受电休克治疗(ECT)评估而入住老年精神科病房。她曾有过一次抑郁发作,始于2007年的乳房肿块切除术后。她的家庭用药方案包括每日服用20毫克他莫昔芬。本病例强调了乳腺癌患者中抑郁症的发病率,探讨了他莫昔芬诱发抑郁症的争议,并评估了在考虑与他莫昔芬存在潜在降低疗效的细胞色素P450 2D6药物相互作用时的抗抑郁药选择。药剂团队在就他莫昔芬药物相互作用对医疗团队进行教育方面发挥了积极作用。经过多次讨论,患者最终除接受ECT治疗外,还在睡前服用15毫克米氮平进行治疗。